middle.news
How Will PainChek Capitalize on FDA Clearance and $5.6M ARR Momentum?
9:16am on Friday 31st of October, 2025 AEDT
•
Healthcare
Read Story
How Will PainChek Capitalize on FDA Clearance and $5.6M ARR Momentum?
9:16am on Friday 31st of October, 2025 AEDT
Key Points
FDA De Novo clearance for PainChek Adult app enables US market entry
Contracted annual recurring revenue rises 18% year-on-year to $5.6 million
115,000 licensed beds across Australia, UK, and Canada with near 100% retention
Launch of PainChek Infant app opens access to a $33.6 billion global market
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Painchek (ASX:PCK)
OPEN ARTICLE